NCT00748046View on ClinicalTrials.gov

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Prostate CancerMetastasesPharmacokinetics
Interventions
DRUG

Radium-223 chloride (BAY88-8223)

The required volume of study drug to be administered to a patient was calculated using the patient's body weight.

Trial Locations (1)

10065

New York

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY